Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information tech… Read more
Haemonetics Corporation (HAE) - Net Assets
Latest net assets as of December 2025: $911.45 Million USD
Based on the latest financial reports, Haemonetics Corporation (HAE) has net assets worth $911.45 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.49 Billion) and total liabilities ($1.58 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $911.45 Million |
| % of Total Assets | 36.59% |
| Annual Growth Rate | 6.91% |
| 5-Year Change | 12.19% |
| 10-Year Change | 14.01% |
| Growth Volatility | 13.24 |
Haemonetics Corporation - Net Assets Trend (1992–2025)
This chart illustrates how Haemonetics Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Haemonetics Corporation (1992–2025)
The table below shows the annual net assets of Haemonetics Corporation from 1992 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $820.84 Million | -14.49% |
| 2024-03-31 | $959.96 Million | +17.35% |
| 2023-03-31 | $818.00 Million | +9.15% |
| 2022-03-31 | $749.42 Million | +2.43% |
| 2021-03-31 | $731.67 Million | +24.62% |
| 2020-03-31 | $587.11 Million | -12.09% |
| 2019-03-31 | $667.87 Million | -11.24% |
| 2018-03-31 | $752.43 Million | +1.73% |
| 2017-03-31 | $739.61 Million | +2.73% |
| 2016-03-31 | $719.98 Million | -12.85% |
| 2015-03-31 | $826.12 Million | -1.61% |
| 2014-03-31 | $839.61 Million | +9.16% |
| 2013-03-31 | $769.18 Million | +4.64% |
| 2012-03-31 | $735.08 Million | +7.13% |
| 2011-03-31 | $686.14 Million | +15.68% |
| 2010-03-31 | $593.12 Million | +9.86% |
| 2009-03-31 | $539.88 Million | +9.25% |
| 2008-03-31 | $494.19 Million | +3.03% |
| 2007-03-31 | $479.65 Million | +8.60% |
| 2006-03-31 | $441.65 Million | +24.36% |
| 2005-03-31 | $355.13 Million | +26.95% |
| 2004-03-31 | $279.75 Million | +25.31% |
| 2003-03-31 | $223.24 Million | -5.74% |
| 2002-03-31 | $236.82 Million | +9.89% |
| 2001-03-31 | $215.52 Million | +4.39% |
| 2000-03-31 | $206.44 Million | -6.97% |
| 1999-03-31 | $221.90 Million | +13.97% |
| 1998-03-31 | $194.70 Million | -13.58% |
| 1997-03-31 | $225.30 Million | +3.82% |
| 1996-03-31 | $217.00 Million | +12.32% |
| 1995-03-31 | $193.20 Million | +20.15% |
| 1994-03-31 | $160.80 Million | +26.91% |
| 1993-03-31 | $126.70 Million | +39.85% |
| 1992-03-31 | $90.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Haemonetics Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 517.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $352.17 Million | 42.90% |
| Common Stock | $482.00K | 0.06% |
| Other Comprehensive Income | $-55.08 Million | -6.71% |
| Other Components | $523.26 Million | 63.75% |
| Total Equity | $820.84 Million | 100.00% |
Haemonetics Corporation Competitors by Market Cap
The table below lists competitors of Haemonetics Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Graham Holdings Co
NYSE:GHC
|
$2.57 Billion |
|
YUNDA Holding Co Ltd
SHE:002120
|
$2.57 Billion |
|
Hainan Mining Co Ltd
SHG:601969
|
$2.57 Billion |
|
ASR Microelectronics Co. Ltd. A
SHG:688220
|
$2.57 Billion |
|
Penske Automotive Group Inc
NYSE:PAG
|
$2.57 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
$2.56 Billion |
|
McGrath RentCorp
NASDAQ:MGRC
|
$2.56 Billion |
|
Waaree Energies Limited
NSE:WAAREEENER
|
$2.56 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Haemonetics Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 959,959,000 to 820,836,000, a change of -139,123,000 (-14.5%).
- Net income of 167,679,000 contributed positively to equity growth.
- Share repurchases of 225,000,000 reduced equity.
- Other comprehensive income decreased equity by 19,452,000.
- Other factors decreased equity by 62,350,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $167.68 Million | +20.43% |
| Share Repurchases | $225.00 Million | -27.41% |
| Other Comprehensive Income | $-19.45 Million | -2.37% |
| Other Changes | $-62.35 Million | -7.6% |
| Total Change | $- | -14.49% |
Book Value vs Market Value Analysis
This analysis compares Haemonetics Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 37.87x to 3.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1992-03-31 | $1.59 | $60.05 | x |
| 1993-03-31 | $2.22 | $60.05 | x |
| 1994-03-31 | $2.78 | $60.05 | x |
| 1995-03-31 | $3.39 | $60.05 | x |
| 1996-03-31 | $3.93 | $60.05 | x |
| 1997-03-31 | $4.11 | $60.05 | x |
| 1998-03-31 | $3.65 | $60.05 | x |
| 1999-03-31 | $4.13 | $60.05 | x |
| 2000-03-31 | $3.90 | $60.05 | x |
| 2001-03-31 | $4.14 | $60.05 | x |
| 2002-03-31 | $4.36 | $60.05 | x |
| 2003-03-31 | $4.46 | $60.05 | x |
| 2004-03-31 | $5.68 | $60.05 | x |
| 2005-03-31 | $6.72 | $60.05 | x |
| 2006-03-31 | $8.04 | $60.05 | x |
| 2007-03-31 | $8.67 | $60.05 | x |
| 2008-03-31 | $9.24 | $60.05 | x |
| 2009-03-31 | $10.31 | $60.05 | x |
| 2010-03-31 | $11.38 | $60.05 | x |
| 2011-03-31 | $13.40 | $60.05 | x |
| 2012-03-31 | $14.25 | $60.05 | x |
| 2013-03-31 | $14.72 | $60.05 | x |
| 2014-03-31 | $16.03 | $60.05 | x |
| 2015-03-31 | $15.86 | $60.05 | x |
| 2016-03-31 | $14.14 | $60.05 | x |
| 2017-03-31 | $14.35 | $60.05 | x |
| 2018-03-31 | $14.06 | $60.05 | x |
| 2019-03-31 | $12.62 | $60.05 | x |
| 2020-03-31 | $11.33 | $60.05 | x |
| 2021-03-31 | $14.26 | $60.05 | x |
| 2022-03-31 | $14.59 | $60.05 | x |
| 2023-03-31 | $15.91 | $60.05 | x |
| 2024-03-31 | $18.68 | $60.05 | x |
| 2025-03-31 | $16.18 | $60.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Haemonetics Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.43%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.32%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 2.99x
- Recent ROE (20.43%) is above the historical average (9.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1992 | 19.87% | 10.20% | 1.22x | 1.60x | $8.94 Million |
| 1993 | 19.57% | 11.47% | 1.20x | 1.42x | $12.13 Million |
| 1994 | 19.59% | 12.68% | 1.08x | 1.43x | $15.42 Million |
| 1995 | 17.39% | 12.80% | 0.94x | 1.45x | $14.28 Million |
| 1996 | 16.54% | 12.90% | 0.97x | 1.33x | $14.20 Million |
| 1997 | 14.65% | 10.65% | 0.96x | 1.44x | $10.47 Million |
| 1998 | -12.74% | -8.68% | 0.85x | 1.73x | $-44.27 Million |
| 1999 | 9.51% | 7.48% | 0.79x | 1.61x | $-1.09 Million |
| 2000 | 9.20% | 6.84% | 0.80x | 1.69x | $-1.65 Million |
| 2001 | 3.36% | 2.46% | 0.85x | 1.60x | $-14.32 Million |
| 2002 | 12.68% | 9.38% | 0.88x | 1.54x | $6.34 Million |
| 2003 | 12.71% | 8.42% | 0.94x | 1.61x | $6.06 Million |
| 2004 | 10.48% | 8.05% | 0.89x | 1.46x | $1.35 Million |
| 2005 | 11.16% | 10.33% | 0.82x | 1.32x | $4.13 Million |
| 2006 | 15.64% | 16.46% | 0.77x | 1.24x | $24.91 Million |
| 2007 | 10.24% | 10.92% | 0.79x | 1.19x | $1.14 Million |
| 2008 | 10.52% | 10.07% | 0.85x | 1.23x | $2.56 Million |
| 2009 | 10.98% | 9.92% | 0.92x | 1.20x | $5.32 Million |
| 2010 | 9.84% | 9.04% | 0.86x | 1.27x | $-937.40K |
| 2011 | 11.66% | 11.82% | 0.81x | 1.21x | $11.37 Million |
| 2012 | 9.10% | 9.19% | 0.80x | 1.24x | $-6.62 Million |
| 2013 | 5.04% | 4.35% | 0.61x | 1.90x | $-38.12 Million |
| 2014 | 4.19% | 3.75% | 0.62x | 1.81x | $-48.81 Million |
| 2015 | 2.05% | 1.86% | 0.61x | 1.80x | $-65.72 Million |
| 2016 | -7.73% | -6.12% | 0.69x | 1.83x | $-127.62 Million |
| 2017 | -3.55% | -2.96% | 0.72x | 1.67x | $-100.23 Million |
| 2018 | 6.06% | 5.04% | 0.73x | 1.64x | $-29.67 Million |
| 2019 | 8.24% | 5.69% | 0.76x | 1.91x | $-11.77 Million |
| 2020 | 13.03% | 7.74% | 0.78x | 2.16x | $17.82 Million |
| 2021 | 10.86% | 9.13% | 0.48x | 2.49x | $6.30 Million |
| 2022 | 5.79% | 4.37% | 0.53x | 2.48x | $-31.57 Million |
| 2023 | 14.11% | 9.87% | 0.60x | 2.37x | $33.60 Million |
| 2024 | 12.25% | 8.98% | 0.60x | 2.29x | $21.56 Million |
| 2025 | 20.43% | 12.32% | 0.56x | 2.99x | $85.60 Million |
Industry Comparison
This section compares Haemonetics Corporation's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Haemonetics Corporation (HAE) | $911.45 Million | 19.87% | 1.73x | $2.57 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |